Compare, Analyse Lupin with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs ACTAVIS (US) - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 LUPIN   ACTAVIS
EQUITY SHARE DATA
    LUPIN
Mar-20
ACTAVIS
Dec-18
LUPIN/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs88214,220-   
Low Rs5059,539-   
Sales per share (Unadj.) Rs339.43,488.2-  
Earnings per share (Unadj.) Rs-5.9-1,123.6-  
Cash flow per share (Unadj.) Rs15.5367.6-  
Dividends per share (Unadj.) Rs6.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs276.714,387.3-  
Shares outstanding (eoy) m453.00332.60-   
Bonus / Rights / Conversions ESOP--  
Price / Sales ratio x2.03.4 60.0%   
Avg P/E ratio x-116.6-10.6 1,103.1%  
P/CF ratio (eoy) x44.832.3 138.7%  
Price / Book Value ratio x2.50.8 303.5%  
Dividend payout %-100.90-   
Avg Mkt Cap Rs m314,2013,951,174 8.0%   
No. of employees `00018.316.9 108.3%   
Total wages/salary Rs m29,8680-   
Avg. sales/employee Rs Th8,400.668,650.1 12.2%   
Avg. wages/employee Rs Th1,632.00-   
Avg. net profit/employee Rs Th-147.2-22,112.2 0.7%   
INCOME DATA
Net Sales Rs m153,7481,160,187 13.3%  
Other income Rs m4,83822,187 21.8%   
Total revenues Rs m158,5851,182,373 13.4%   
Gross profit Rs m24,84930,403 81.7%  
Depreciation Rs m9,702495,955 2.0%   
Interest Rs m3,63066,949 5.4%   
Profit before tax Rs m16,355-510,315 -3.2%   
Minority Interest Rs m40-   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,521130,151 -5.8%   
Tax Rs m11,571-6,467 -178.9%   
Profit after tax Rs m-2,694-373,697 0.7%  
Gross profit margin %16.22.6 616.8%  
Effective tax rate %70.81.3 5,582.9%   
Net profit margin %-1.8-32.2 5.4%  
BALANCE SHEET DATA
Current assets Rs m154,132475,848 32.4%   
Current liabilities Rs m92,252420,951 21.9%   
Net working cap to sales %40.24.7 850.6%  
Current ratio x1.71.1 147.8%  
Inventory Days Days8220 419.1%  
Debtors Days Days12966 195.0%  
Net fixed assets Rs m89,082131,327 67.8%   
Share capital Rs m9060-   
"Free" reserves Rs m124,4610-   
Net worth Rs m125,3674,785,228 2.6%   
Long term debt Rs m17,9331,685,052 1.1%   
Total assets Rs m249,8397,480,400 3.3%  
Interest coverage x5.5-6.6 -83.1%   
Debt to equity ratio x0.10.4 40.6%  
Sales to assets ratio x0.60.2 396.8%   
Return on assets %0.4-4.1 -9.1%  
Return on equity %-2.1-7.8 27.5%  
Return on capital %8.7-4.8 -180.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m31,9800-   
CASH FLOW
From Operations Rs m14,688414,491 3.5%  
From Investments Rs m11,070227,709 4.9%  
From Financial Activity Rs m-8,906-711,391 1.3%  
Net Cashflow Rs m16,853-68,845 -24.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 73.49 Rs / USD

Compare LUPIN With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare LUPIN With: DR. REDDYS LAB  ABBOTT INDIA  FULFORD INDIA  ORCHID PHARMA  TORRENT PHARMA  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views On News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

More Views on News

Most Popular

Is Intraday Trading For You? (Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks (Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution (Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

New Research: Our #1 Stock Pick Right Now
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

LUPIN SHARE PRICE


May 14, 2021 (Close)

TRACK LUPIN

MORE ON LUPIN

LUPIN 5-YR ANALYSIS

COMPARE LUPIN WITH

FEATURED VIDEOS

Top Pick for Next Decade

The 'Big' Money is in this 'Small' Detail

Stability, Quality or Green Stocks for 2021?

Market Crash: Picture Abhi Baaki Hai?

More Featured Videos

MARKET STATS